Adapts emergency protocols for pediatric patients using weight-based dosing and Broselow methodology. Use when treating pediatric emergencies, calculating pediatric doses, or managing pediatric resuscitations.
Adapts emergency protocols for pediatric patients using weight-based dosing, age-adjusted vital sign norms, and the Broselow tape methodology for equipment sizing and medication dosing.
Children are not small adults — their physiology, anatomy, pharmacokinetics, and disease presentations differ fundamentally from adults. Medication errors in pediatric emergency care occur at 3 times the rate of adult care, with dosing errors being the most common type. A 10-fold dosing error — the most dangerous medication error in pediatrics — occurs in approximately 1 in 1,000 pediatric ED visits and can be lethal with medications like epinephrine, insulin, and opioids.
The Broselow-Luten system provides length-based weight estimation and pre-calculated equipment sizes and drug doses. PALS (Pediatric Advanced Life Support) protocols from the AHA define resuscitation algorithms, and the Emergency Medical Services for Children (EMSC) program sets national standards for pediatric emergency readiness. Only 18% of US emergency departments meet all pediatric readiness standards, making systematic protocol adherence essential for safe pediatric emergency care.
| Age | Heart Rate | Respiratory Rate | SBP (mmHg) | Weight (kg) |
|---|---|---|---|---|
| Newborn | 120-160 | 30-60 | 60-80 | 3-4 |
| 1-12 months | 100-160 | 25-40 | 70-100 | 4-10 |
| 1-3 years | 90-150 | 20-30 | 80-110 | 10-15 |
| 4-5 years | 80-140 | 20-25 | 85-110 | 16-20 |
| 6-12 years | 70-120 | 15-20 | 90-120 | 20-40 |
| 13-18 years | 60-100 | 12-20 | 100-130 | 40-70 |
Minimum acceptable SBP by age: SBP = 70 + (age in years × 2) for ages 1-10. SBP <90 for age >10.
Rapid across-the-room assessment before touching the child:
| PAT Result | Interpretation | Urgency |
|---|---|---|
| All normal | Stable | Continue systematic evaluation |
| Abnormal appearance only | CNS dysfunction or systemic illness | High priority |
| Abnormal breathing only | Respiratory distress | Immediate respiratory support |
| Abnormal appearance + breathing | Respiratory failure | Immediate intervention |
| Abnormal appearance + circulation | Compensated shock → decompensating | Immediate fluid resuscitation |
| All abnormal | Cardiopulmonary failure | Resuscitation team activation |
| Medication | Dose | Route | Max Single Dose | Notes |
|---|---|---|---|---|
| Epinephrine (cardiac arrest) | 0.01 mg/kg (0.1 mL/kg of 1:10,000) | IV/IO | 1 mg | NEVER use 1:1,000 concentration IV |
| Epinephrine (anaphylaxis) | 0.01 mg/kg (0.01 mL/kg of 1:1,000) | IM | 0.3 mg (<30 kg), 0.5 mg (≥30 kg) | Anterolateral thigh |
| Atropine | 0.02 mg/kg | IV/IO | 0.5 mg | Minimum dose 0.1 mg (below this may cause paradoxical bradycardia) |
| Amiodarone | 5 mg/kg | IV/IO | 300 mg | For VF/pulseless VT |
| Adenosine | 0.1 mg/kg (1st), 0.2 mg/kg (2nd) | Rapid IV push | 6 mg (1st), 12 mg (2nd) | Must be rapid push with flush |
| Dextrose | D10W: 5 mL/kg; D25W: 2 mL/kg | IV | — | D50 is NOT used in children <8 years |
| Diazepam (status epilepticus) | 0.2 mg/kg | IV; 0.5 mg/kg rectal | 10 mg IV; 20 mg rectal | Second-line after midazolam |
| Midazolam (status epilepticus) | 0.1 mg/kg IV; 0.2 mg/kg IM/IN | IV/IM/IN | 10 mg | First-line for active seizures |
| Ceftriaxone (meningitis) | 50 mg/kg | IV | 2 g | Do not delay for LP |
Shockable rhythms (VF / pulseless VT):
Non-shockable rhythms (asystole / PEA):
| Color | Weight (kg) | ETT (uncuffed) | ETT (cuffed) | Laryngoscope | NG Tube |
|---|---|---|---|---|---|
| Grey | 3-5 | 3.5 | 3.0 | Miller 1 | 8 Fr |
| Pink | 6-7 | 3.5-4.0 | 3.0-3.5 | Miller 1 | 8 Fr |
| Red | 8-9 | 4.0 | 3.5 | Miller 1-2 | 10 Fr |
| Purple | 10-11 | 4.5 | 4.0 | Miller 2 | 10 Fr |
| Yellow | 12-14 | 5.0 | 4.5 | Mac 2 | 12 Fr |
| White | 15-18 | 5.5 | 5.0 | Mac 2 | 12 Fr |
| Blue | 19-23 | 6.0 | 5.5 | Mac 2 | 14 Fr |
| Orange | 24-29 | 6.5 | 6.0 | Mac 3 | 14 Fr |
| Green | 30-36 | 7.0 | 6.5 | Mac 3 | 16 Fr |
| Age | Approach | Key Concern |
|---|---|---|
| 0-28 days | Full sepsis workup: CBC, blood culture, UA + culture, LP, CXR; admit + empiric antibiotics (ampicillin + gentamicin or cefotaxime) | Late-onset GBS, E. coli, HSV; HSV PCR if risk factors |
| 29-60 days | Risk stratify using Rochester/Philadelphia/Step-by-Step criteria; low-risk may be managed outpatient with close follow-up | Serious bacterial infection rate 7-10% |
| 61-90 days | UA + culture; blood culture if ill-appearing; LP if <2 months or ill-appearing | UTI is the most common source |
| 3-36 months | Evaluate for UTI (especially uncircumcised males <6 months, females <2 years); CXR if respiratory symptoms | Pneumonia, UTI, occult bacteremia (now rare post-PCV13) |